Sana Biotechnology (SANA) Operating Expenses (2020 - 2026)

Sana Biotechnology has reported Operating Expenses for 7 years, with the latest figure at $48.6 million in Q1 2026.

• Quarterly Operating Expenses fell 3.98% year-over-year to $48.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.7 million (down 9.48% YoY) and the FY2025 annual result came in at $9.3 million, down 37.72% from the prior year.
• Operating Expenses rose to $48.6 million in Q1 2026 per SANA's latest filing, from $2.8 million in the prior quarter.
• Over five years, Operating Expenses peaked at $116.3 million in Q2 2023 and troughed at -$182.2 million in Q4 2023.
• A 5-year average of $10.0 million and a median of $4.1 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses tumbled 245.76% in 2022, then jumped 1147.35% in 2025.
• Over 5 years, Operating Expenses stood at -$162.2 million in 2022, then fell by 12.33% to -$182.2 million in 2023, then soared by 101.43% to $2.6 million in 2024, then climbed by 6.56% to $2.8 million in 2025, then soared by 1651.22% to $48.6 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $48.6 million, $2.8 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.